利拉鲁肽联合甘精胰岛素对于新诊断2型糖尿病患者降糖调脂作用的临床分析  

Clinical Analysis of the Effect of Liraglutide Combined with Insulin Glargine on Hypoglycemic and Lipid-lowering Effects in Newly Diagnosed Type 2 Diabetic Patients

作　　者：聂礼强 周立新 翟云 买买提明·喀迪尔 NIE Liqiang;ZHOU Lixin;ZHAI Yun;Maimaitiming Kadier(Department of Hematology and Endocrinology,Army Hospital of No.947,Shule,Xinjiang Uygur Autonomous Region,844200 China)

机构地区：[1]陆军第九四七医院血液内分泌科,新疆疏勒844200

出　　处：《中外医疗》2021年第23期89-92,共4页China & Foreign Medical Treatment

摘　　要：目的研究利拉鲁肽联合甘精胰岛素对新诊断2型糖尿病(T2DM)患者降糖、调脂的作用效果。方法随机选取该院内分泌科2018年8月—2020年7月新诊断T2DM患者100例,随机分成两组。观察组(50例)采用利拉鲁肽联合甘精胰岛素治疗,对照组(50例)采用强化胰岛素治疗。观察两组患者治疗前后血糖与胰岛功能、体质量、血脂的指标变化。结果与治疗前相比,两组空腹血糖(FPG)、餐后2 h血糖(PBG)、糖化血红蛋白(HbA1c)、空腹C肽(FCP)、餐后2 h C肽(PCP)、胰岛素抵抗指数(HOMA-IR)、总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)和体质量、体质指数(BMI)下降,胰岛β细胞功能指数(HOMA-β)和高密度脂蛋白胆固醇(HDL-C)升高。治疗1个月后,FPG、2 hPBG、HbA1c、FCP、2 hPCP、HOMA-IR、HOMA-β、体质量、BMI、TC、TG、LDL-C、HDL-C的指标分别为(7.22±0.59)mmol/L、(15.01±3.25)mmol/L、(8.04±0.73)%、(714.37±11.73)pmol/L、(1708.35±108.49)pmol/L、(1.85±0.37)、(51.49±8.16)%、(66.36±10.14)kg、(25.05±3.31)kg/m2、(4.25±0.89)mmol/L、(2.37±0.76)mmol/L、(2.75±0.89)mmol/L、(1.14±0.09)mmol/L,均显著优于对照组,差异有统计学意义(t=9.417、3.297、7.243、26.685、20.767、2.063、7.009、4.134、2.748、3.555、5.442、2.369、13.333,P<0.05)。治疗3个月后,FBG、2 hPBG、HbA1c、FCP、2 hPCP、HOMA-IR、HOMA-β、体质量、BMI、TC、TG、LDL-C、HDL-C的指标分别为(6.13±0.35)mmol/L、(11.38±2.23)mmol/L、(6.52±0.46)%、(661.21±10.58)pmol/L、(1448.23±61.08)pmol/L、(1.45±0.28)、(76.53±8.73)%、(64.11±8.37)kg、(24.01±2.60)kg/m2、(3.31±0.77)mmol/L、(1.89±0.58)mmol/L、(2.01±0.64)mmol/L、(1.93±0.13)mmol/L,均显著优于对照组,差异有统计学意义(t=17.272、6.429、13.611、24.691、12.061、4.877、10.864、2.297、2.115、10.035、8.386、7.094、38.201,P<0.05)。结论新诊断T2DM患者联合利拉鲁肽与甘精胰岛素治疗,在降糖、调脂方面明显优于强化胰岛素治疗,且�Objective To study the effect of liraglutide combined with insulin glargine on hypoglycemic and lipid-lowering effects in newly diagnosed type 2 diabetes(T2DM)patients.Methods A total of 100 newly diagnosed T2DM patients from the Department of Endocrinology in the hospital from August 2018 to July 2020 were randomly selected and divided into two groups.The observation group(50 cases)was treated with liraglutide combined with insulin glargine,and the control group(50 cases)was treated with intensive insulin.Observe the changes of blood glucose and islet function,body mass,and blood lipids of the two groups of patients before and after treatment.Results Compared with before treatment,the two groups of fasting blood glucose(FPG),2 hours postprandial blood glucose(2 hPBG),glycosylated hemoglobin(HbA1c),fasting C peptide(FCP),2 hours postprandial C peptide(PCP),insulin resistance Index(HOMA-IR),total cholesterol(TC),triacylglycerol(TG),low-density lipoprotein cholesterol(LDL-C)and body mass,body mass index(BMI)decreased,pancreaticβ-cell function index(HOMA-β)and high-density lipoprotein cholesterol(HDL-C)were elevated.After 1 month of treatment,the indexes of FPG,2 hPBG,HbA1c,FCP,2 hPCP,HOMA-IR,HOMA-β,body mass,BMI,TC,TG,LDL-C,HDL-C were(7.22±0.59)mmol/L,(15.01±3.25)mmol/L,(8.04±0.73)%,(714.37±11.73)pmol/L,(1708.35±108.49)pmol/L,(1.85±0.37),(51.49±8.16)%,(66.36±10.14)kg,(25.05±3.31)kg/m2,(4.25±0.89)mmol/L,(2.37±0.76)mmol/L,(2.75±0.89)mmol/L,(1.14±0.09)mmol/L,were significantly better than the control group,and the difference were statistically significant(t=9.417,3.297,7.243,26.685,20.767,2.063,7.009,4.134,2.748,3.555,5.442,2.369,13.333,P<0.05).After 3 months of treatment,the indexes of FBG,2 hPBG,HbA1c,FCP,2 hPCP,HOMA-IR,HOMA-β,body mass,BMI,TC,TG,LDL-C,HDL-C were(6.13±0.35)mmol/L,(11.38±2.23)mmol/L,(6.52±0.46)%,(661.21±10.58)pmol/L,(1448.23±61.08)pmol/L,(1.45±0.28),(76.53±8.73)%,(64.11±8.37)kg,(24.01±2.60)kg/m2,(3.31±0.77)mmol/L,(1.89±0.58)mmol/L,(2.01±0.64)mmol/L,(1.93±0.13)mmol/L,were

关 键 词：利拉鲁肽 联合 甘精胰岛素 新诊断2型糖尿病 降糖调脂 

分 类 号：R4[医药卫生—临床医学]